Compare Enveric Biosciences Inc (ENVB) vs Mattel Inc (MAT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Mattel Inc — how do they compare? Enveric Biosciences Inc trades at $1.48 (market cap $6.80M), while Mattel Inc trades at $17.05 (market cap $4.74B). The key difference: Mattel Inc is far larger — about 697.1× Enveric Biosciences Inc's market cap, and Mattel Inc is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Mattel Inc for 97 Days on average.
| ENVB | MAT | |
|---|---|---|
Market Cap | $6.80M | $4.74B |
Volume | 64,867 | 11,809,722 |
Sector | Health | Consumer Cyclical |
52-Week High | $10.80 | $22.16 |
52-Week Low | $1.27 | $12.66 |
Typical Hold Time | 14 Days | 97 Days |
Enterprise Value | -$1.49M | $6.96B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.45, down 3.01% on the day, with a bearish technical signal driven by moving averages. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten quarterly EPS expectations. Recent positive developments include a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in investor conferences.
The outlook is mixed; analyst consensus is 75% buy with strong earnings beats, but high negative ROE/ROA and operational cash burn pose significant risks. Investment opportunity hinges on successful drug development, while key risks include funding needs and clinical trial outcomes.
Mattel (MAT) trades at $17.12, up 4.58% amid takeover speculation from Authentic Brands Group. The stock shows bullish technical signals with strong moving average support, though RSI levels indicate overbought conditions. Fundamentally, the company maintains solid profitability with 7.78% net margins and 20.5% ROE, though recent earnings have been mixed with two misses in the last three quarters. Leadership transition is underway with Roger Lynch replacing Ynon Kreiz as CEO.
The takeover interest creates near-term upside potential, but execution risks remain under new leadership. Analyst consensus is bullish with 53% buy ratings and $15 price target, though current price exceeds target. Key risks include Barbie sales deterioration, integration challenges for new CEO, and declining operating cash flow from $870M in 2023 to $593M in 2025.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Mattel Inc
Mattel markets toy products that are sold to its wholesale customers and direct to retail consumers. The company offers products for children and families, including toys for infants and preschoolers, girls and boys, youth electronics, handheld and other games, puzzles, educational toys, media-driven products, and plush and fashion-related toys. Mattel's owned portfolio includes Barbie, Hot Wheels, Fisher-Price, Thomas & Friends, and American Girl. In addition, it currently manufactures toy products for its segments both internally and externally (through manufacturing partners). Just over half of its net sales are in North America, while the remainder stem from international markets.
Read more on MAT →
